<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04843267</url>
  </required_header>
  <id_info>
    <org_study_id>B2020-324-01</org_study_id>
    <nct_id>NCT04843267</nct_id>
  </id_info>
  <brief_title>A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT</brief_title>
  <official_title>A Multi-center, Non-randomized, Open-label Phase II Clinical Study on the Treatment of Newly Diagnosed Advanced Hodgkin's Lymphoma With PD-1 Antibody (Tislelizumab) Combined With AVD Regimen (Doxorubicin, Vindesine, Dacarbazine) Under the Guidance of PET/CT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The experimental drug regimen in this study includes a PD-1 antibody (tislelizumab)&#xD;
      single-drug induction treatment period and a PD-1 antibody + AVD combined treatment period.&#xD;
&#xD;
        1. PD-1 antibody (tislelizumab) single-drug induction treatment period (first 2 courses for&#xD;
           all patients + 3-6 courses for CR patients):&#xD;
&#xD;
           PD-1 antibody (tislelizumab), specification: 100mg/bottle. Usage and dosage: intravenous&#xD;
           drip, 200mg each time, QD, D1. In the above PD-1 antibody single-drug regimen, 21 days&#xD;
           are regarded as a treatment cycle, and all patients first receive 2 courses of PD-1&#xD;
           antibody single-drug induction treatment;&#xD;
&#xD;
        2. PET/CT mid-term efficacy evaluation used for guiding follow-up treatment options:&#xD;
&#xD;
           PET/CT efficacy evaluation before the 3rd course of treatment (PET/CT2):&#xD;
&#xD;
           CR patients: continue to receive PD-1 antibody monotherapy, and then receive 4 courses&#xD;
           of PD-1 antibody therapy; PR patients: sequential 4 courses of PD-1 antibody + AVD&#xD;
           combined chemotherapy; PD+SD patients: out group, and receive other anti-lymphoma&#xD;
           therapy deemed suitable by the investigators;&#xD;
&#xD;
           After the 6th course, patients not out of the group receive PET/CT3 efficacy evaluation:&#xD;
&#xD;
           CR patients: end the treatment and enter the follow-up; PR patients: receive 2 more&#xD;
           courses of PD-1 antibody + AVD combined chemotherapy, and then enter the follow-up.&#xD;
&#xD;
        3. PD-1 antibody + AVD combined treatment period (3rd-6th/8th course for PR patients):&#xD;
&#xD;
      PD-1 antibody, specification: 100mg/bottle. Usage and dosage: intravenous drip, 100mg each&#xD;
      time, QD, d1, d15. AVD regimen Doxorubicin 25mg/m2, d1, d15 intravenous injection Vindesine&#xD;
      3mg/m2, d1, d15 intravenous injection Dacarbazine 0.375mg/m2, d1, d15 intravenous drip In&#xD;
      this combined treatment regimen, every 28 days is a treatment cycle, and the PD-1 antibody is&#xD;
      used in combination with AVD in D1 and D15 of each treatment cycle.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete response rate after two cycles of tislelizumab</measure>
    <time_frame>6 weeks</time_frame>
    <description>complete response rate after two cycles of tislelizumab by PET/CT</description>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Chemotherapy Effect</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab</intervention_name>
    <description>Tislelizumab in first-line treatment of Hodgkin's lymphoma</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with newly diagnosed classical Hodgkin lymphoma (HL) confirmed by&#xD;
             histopathology;&#xD;
&#xD;
          2. Stage III-IV, or Stage IIB patients with at least one high-risk factor (NCCN standard)&#xD;
&#xD;
          3. Patients not suitable for receiving radiotherapy subsequently&#xD;
&#xD;
          4. Patients with at least one assessable lesion (according to Lugano 2014 standard);&#xD;
&#xD;
          5. Age 18 or above (including 18), no gender requirement;&#xD;
&#xD;
          6. ECOG PS score of 0-1 points;&#xD;
&#xD;
          7. Expected survival time ≥ 3 months;&#xD;
&#xD;
          8. Hematopoietic function: absolute neutrophil count ≥ 1.5×109/L, platelets ≥ 90×109/L,&#xD;
             hemoglobin ≥ 90g/L; liver function: for patients with non-hepatitis B, total&#xD;
             bilirubin, ALT and AST &lt;1.5×ULN (upper limit of normal); patients with hepatitis B&#xD;
             need to take effective antiviral drugs, and HBV-DNA copy &lt;2000 IU/ml and ALT&lt;2×ULN;&#xD;
             renal function: creatinine &lt;1.5×ULN and creatinine clearance rate ≥50ml/min;&#xD;
&#xD;
          9. With normal main indicators of cardio-pulmonary function, and no obvious&#xD;
             contraindication to chemotherapy;&#xD;
&#xD;
         10. Not received any anti-tumor therapy such as radiotherapy, chemotherapy, targeted&#xD;
             therapy, cellular immunotherapy or hematopoietic stem cell transplantation before&#xD;
             enrollment;&#xD;
&#xD;
         11. Voluntarily signing an informed consent form before trial screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Nodular lymphocyte predominant HL;&#xD;
&#xD;
          2. Patients received any form of anti-tumor therapy in the past;&#xD;
&#xD;
          3. Patients planning to receive radiotherapy or autologous stem cell transplantation;&#xD;
&#xD;
          4. With involvement of central nervous system (meninges or brain parenchyma);&#xD;
&#xD;
          5. Pregnant and lactating women and child-bearing patients who are unwilling to take&#xD;
             contraceptive measures;&#xD;
&#xD;
          6. Patients with history of other tumors, except for cured cervical cancer orskin basal&#xD;
             cell carcinoma; patients who have received organ transplantation;&#xD;
&#xD;
          7. Patients who have received symptomatic treatment of myelosuppressive toxicity within 7&#xD;
             days before enrollment;&#xD;
&#xD;
          8. Patients who have used any immunosuppressive drugs within 4 weeks before the&#xD;
             first-dose treatment,&#xD;
&#xD;
          9. Patients with known active interstitial pneumonia;&#xD;
&#xD;
         10. Abnormal liver function (total bilirubin&gt;1.5×ULN, ALT/AST&gt;2.5×ULN or ALT/AST&gt;5×ULN for&#xD;
             patients with liver invasion), abnormal renal function (serum creatinine&gt;1.5×ULN),&#xD;
             abnormal electrolyte metabolism;&#xD;
&#xD;
         11. Peripheral neuropathy ≥ Grade 2;&#xD;
&#xD;
         12. Patients with a history of prolonged QT interval which is of clinical significance&#xD;
             (male&gt; 450ms, female&gt; 470ms), ventricular tachycardia (VT), atrial fibrillation (AF),&#xD;
             heart block, myocardial infarction (MI) within 1 year, congestive heart failure (CHF),&#xD;
             patients with symptomatic coronary heart disease requiring drug therapy;&#xD;
&#xD;
         13. Patients with the end-diastolic width of fluid sonolucent area in pericardial cavity&#xD;
             ≥10mm by cardiac B-ultrasonography;&#xD;
&#xD;
         14. Mentally disturbed/patients unable to give informed consent;&#xD;
&#xD;
         15. Patients who affect the evaluation of test results due to drug abuse or long-term&#xD;
             alcohol abuse;&#xD;
&#xD;
         16. Participating in another interventional clinical study at the same time; Patients not&#xD;
             suitable to participate in this trial by the judgment of investigators.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiming Li</last_name>
      <phone>+86-020-87343765</phone>
      <email>lizhm@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 12, 2021</study_first_submitted>
  <study_first_submitted_qc>April 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Li Zhiming</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

